77 results about "Liver Insufficiency" patented technology

The invention relates to application of DR5 in preparation of a detection system for hepatic failure risk prognosis. The invention also relates to application of the combination of the DR5, TBIL and INR markers in evaluating the risk of hepatic failure. The DR5 single index and the DR5, TBIL and INR three-index model provided by the invention are especially suitable for liver failure risk prediction on the basis of liver cancer. Compared with an existing model, the DR5 single index model and the DR5, TBIL and INR three-index model are excellent in sensitivity, specificity and area difference under an AUC curve, and a more accurate prediction result can be obtained. At present, part of patients possibly and rapidly develop into hepatic failure even under the condition that liver cirrhosis does not exist, and the hepatic failure phenomenon in the early stage of liver cirrhosis is difficult to detect in time. The DR5 single index and the DR5, TBIL and INR three-index model provided by the invention can solve the problem of difficulty in early accurate diagnosis of ACLF caused by pure dependence on traditional biochemical and blood coagulation indexes.

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

The invention relates to a construction method of a model for preoperative evaluation of postoperative complications of hepatic resection. Performing high-order interactive modeling on the plurality of preoperative characteristic variables, and identifying the potential influence of the multi-factor joint effect on the postoperative complications; comprising the interaction between hepatic insufficiency and diabetes and the relationship between preoperative anemia and malnutrition; using a decision tree model to screen out features matched with the complication risk by calculating each variable and interaction item; for the modeling of the nonlinear relationship between the variables, capturing the nonlinear relationship between the variables by adopting a support vector machine (SVM) method; the prediction of the increase of the preoperative liver hardness is in a non-linear relationship with the risk of postoperative complications; constructing a multi-level regression model including hierarchical Bayesian regression, performing risk assessment on different levels including an individual level and a group level, and integrating individual differences and group features of patients; and each layer of model independently evaluates different risk factors, and integrates data of different layers for prediction.

The present invention relates to a specific liver microtissue comprising at least three different phenotypes of liver cells obtained from induced pluripotent stem cells encapsulated in a single three-dimensional closed microcompartment. The invention also relates to a method for preparing the liver micro-tissue and application of the liver micro-tissue in treating or preventing liver failure.

Methods and uses of increasing or accelerating liver regeneration in a subject in need thereof are provided. In some aspects, such methods and uses comprise administering an effective amount of an androgen receptor inhibitor to a subject in need thereof, including, but not limited to, a subject suffering from one or more risk factors of post-hepatectomy liver failure. Any androgen receptor is contemplated for use in the methods described herein including, but not limited to, enzalutamide, apalutamide, bicalutamide, darolutamide, flutamide, nilutamide, or proxalutamide.

The invention belongs to the technical field of biomedical engineering, and discloses a multiple biomarker detection system for diagnosis and classification of hepatic failure acute kidney injury, comprising a biomarker library construction module for obtaining historical hepatic failure acute kidney injury data to construct a biomarker library; the historical hepatic failure acute kidney injury data comprises biomarker data, pathological image data and patient clinical data; the data processing module is used for preprocessing the acquired biomarker data, pathological image data and patient clinical data to obtain a biomarker feature data set, a pathological image feature data set and a clinical feature data set; the acute kidney injury diagnosis module is used for fusing the biomarker feature data set, the pathological image feature data set and the clinical feature data set to obtain a comprehensive feature data set; inputting the comprehensive feature data set into a trained acute kidney injury diagnosis model, and predicting to obtain acute kidney injury type data; and the diagnosis accuracy is improved.

The present invention relates to compounds of formula 1: # imgabs0 # and their use as STING antagonists, for example, the composition is used for treating diseases selected from the group consisting of systemic lupus erythematosus (SLE), (single and double gene) interferon diseases (including STING-related vascular disease (SAVI), Aicardi-Goutires syndrome (AGS), COPA syndrome and familial chilblain-like lupus, DNASE2 or ATAD3A gene mutated type I interferon disease, age-related macular degeneration (AMD), retinopathy, glaucoma, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, and lupus erythematosus. Amyotrophic lateral sclerosis (ALS), diabetes, obesity, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, sicca syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), dermatomyositis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic plus acute liver failure (ACLF), interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), and the like. , aging / muscle disease, sepsis, heart failure, rheumatoid arthritis, and osteoarthritis.

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.

To provide methods of inducing formation of liver organoids from precursor cells, such as iPSC cells, which can be used for screening for a serious adverse event (SAE), such as liver failure and / or drug induced liver injury (DILI), and / or drug toxicity.SOLUTION: This method comprises the steps of a) contacting definitive endoderm (DE) derived from iPSC cells with a FGF pathway activator and a GSK3 inhibitor, for a period of time sufficient to form posterior foregut spheroids, and b) incubating the posterior foregut spheroids obtained in the step a in the presence of retinoic acid (RA) for a period of time sufficient to form the liver organoid.SELECTED DRAWING: Figure 1

Methods and compositions of matter useful for preventing or reversing liver failure. Autologous hepatic progenitors are generated from pluripotent stem cells and administered in a manner to augment and / or replace endogenous regenerative processes. Generation of "adjuvant cells" to enhance engraftment and function of hepatic progenitors. Compositions and methods of reversing liver fibrosis whether caused by viral or chemical toxicity.

The invention belongs to the field of biomedicine, and particularly relates to a construction method of an in-situ biological 3D printing artificial liver patch for treating hepatic failure. The main component of the artificial liver patch disclosed by the invention is composite hydrogel, and the composite hydrogel comprises hyaluronic acid (HA), gelatin (Gelatin), sodium alginate (sodium alginate) and methacrylated gelatin (GelMA). The composite hydrogel has good 3D printing performance, large-scale construction of the artificial liver patch can be achieved through biological 3D printing, and a potential solution is provided for transplantable biological artificial liver tissue. The artificial liver patch adopts an extrusion type printing mode, the forming speed is high, internal liver cells can still keep high activity, reconstruction of liver basic functions (glycogen storage, drug metabolism, secretory protein synthesis and the like) can be guaranteed, and the artificial liver patch has important potential in treatment of liver failure diseases.

The invention relates to application of serum mucoid or Tax1 binding protein 1 in preparation of a medicine for treating medicine-induced liver injury or organ ischemia-reperfusion injury. Experiments prove that by using an adeno-associated virus (AAV) carrying an Orm2 gene, ORM2 recombinant protein or knocking down a TAX1BP1 gene, liver injury and liver failure, ischemia reperfusion injury of the liver, ischemia reperfusion injury of the kidney and ischemia reperfusion induction of intestines induced by APAP treatment can be effectively relieved, and the application has the advantages that the liver injury and liver failure, the ischemia reperfusion injury of the kidney and the ischemia reperfusion induction of the intestine can be effectively relieved; and a new target spot and a new treatment method are provided for treating the ferroptosis-related organ injury.

The invention discloses an application of an epoxidase type II inhibitor, the application is the application in preparation of drugs for treating liver injury, hepatitis, hepatic fibrosis, or liver function decline or complications thereof, and the application discovers that the existing COX-2 selective inhibitors such as celecoxib and the like and a novel efficient COX-2 selective inhibitor 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, the 2, 8-deuterated dimethyl-2-(trifluoromethyl)-2H-benzopyran-3-carboxylic acid disclosed by the invention has the effects of remarkably relieving liver injury, reducing necrosis focus and inflammatory cell infiltration of liver cells and resisting cholestatic hepatic fibrosis; in addition, hepatocyte lipid accumulation and ballooning induced by high fat diet can be reduced, and the progress of lipid hepatitis is remarkably inhibited; it is found for the first time that the traditional Chinese medicine composition can significantly reduce the concentration of serum bilirubin and play a role in relieving hyperbilirubinemia caused by liver injury or liver insufficiency; the traditional Chinese medicine composition can be used for treating neonatal jaundice, congenital bile duct atresia, cholestatic cirrhosis, acute toxic hepatic failure, bilirubin increase caused by acute attack of chronic hepatitis, chronic hepatic failure or hepatic encephalopathy and the like; therefore, the method has obvious economic benefit and clinical application value.

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

Use of targeted inhibition of p300 / CBP in treating liver injury diseases, and a method for preventing and / or treating liver injury diseases by targeted inhibition of p300 / CBP in a subject in need thereof, the liver injury diseases comprising acute liver injury, chronic liver injury and / or liver failure, and acute-on-chronic liver failure. A p300 / CBP inhibitor has broad market application prospects in the treatment of acute and chronic liver injury and / or liver failure and acute-on-chronic liver failure.

The application belongs to the technical field of biological detection, and particularly relates to the use of apolipoprotein A-I in the preparation of a diagnostic reagent or system for predicting the risk of severe acute hepatitis E. The application first discloses and verifies the significant correlation between the serum apolipoprotein A-I (apoA-I) level and the adverse clinical outcomes (including severe jaundice, liver failure and death) of patients with acute hepatitis E, and establishes the risk interpretation threshold (0.675 g / L and 0.435 g / L) with clinical practical value. The application can objectively and early identify high-risk patients, and provides a powerful auxiliary tool for clinical stratified management and resource optimization.

It refers to a dietary product for hypoproteic diet suitable for supplementing the diet in patients suffering from chronic kidney disease, hepatic insufficiency and urea cycle disorders. It also refers to the use of the dietary product as supplement of the diet of said patients. The dietary product comprises amino acids, amino acid analogues, and pharmaceutically acceptable excipients.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The invention discloses a preparation method and application of a hepatic parenchymal cell targeting gene delivery system, and relates to construction and preparation of a hepatic parenchymal cell targeting lipid material GalNAc-PEG2000-DSPE modified MKK4-siRNA (siMKK4) loaded lipid nanoparticle gene delivery system GalNAc-LNP-siMKK4, and the hepatic parenchymal cell targeting gene delivery system can be used for active targeting gene therapy of hepatic failure. The parenchymal hepatic cell targeted gene delivery system selects siMKK4 as a liver regeneration promoting gene therapy drug, has the advantages of clear target spot and capability of accurately silencing a target gene, and can protect siMKK4 from being degraded by extracellular nuclease as a gene delivery carrier, so that the targeted gene delivery system has a good application prospect. N-acetylgalactosamine (GalNAc) is selected as a target head, so that therapeutic genes can be precisely targeted and delivered to parenchymal hepatic cells, the risk of tumorigenesis of other parts of an organism can be reduced while liver regeneration is promoted, and a new thought and a new method are provided for liver regeneration treatment of hepatic failure patients.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Yellow Fever Virus (YFV) viral genome expression. Also disclosed are pharmaceutical compositions that include YFV RNAi agents and methods of use thereof. The YFV RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the YFV RNAi agents in vivo provides for inhibition of YFV viral genome expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms caused by YFV infection, such as liver failure.

Compositions of matter and therapeutic methods for preventing, reducing, or reversing liver pathologies. Autologous pluripotent stem cells for generating monocytes or macrophages that are capable of suppressing liver failure. Methods of administering monocytes that are engineered or induced to facilitate hepatic regeneration. Hepatogenic cells such as monocytes are generated from induced pluripotent stem cells. Hepatogenic cells can be generated by overexpression of one or a plurality of factors associated with an M2 phenotype in pluripotent stem cell-derived monocytes such as signal transducer and activator of transcription 6 (STAT6) and transforming growth factor-beta. Hepatogenic monocytes can be generated in an environment that simulates liver injury.

The present invention relates to compounds for use in the treatment of liver failure.

The invention provides a capecitabine prodrug for reducing liver metabolism burden and application thereof, a derivative formed by introducing a masking group R capable of enzymolysis or chemical hydrolysis into 5 '-hydroxyl or N-amino of a capecitabine molecule, and the R is selected from amino-acid ester, phosphate, polyethylene glycol chain or cholic acid conjugation group. The prodrug can be selectively activated in intestinal tracts or tumor tissues through a non-UGT1A1 dependent pathway, and 5-fluorouracil is finally released through metabolism. Due to the characteristic, the competitive inhibition of the prototype capecitabine on liver UGT1A1 enzyme is obviously reduced, and the interference on bilirubin binding and excretion pathways is fundamentally reduced. The pharmaceutical composition disclosed by the invention is suitable for patients with UGT1A1 gene defects or liver insufficiency. While good anti-tumor activity is maintained, the hepatotoxicity is remarkably reduced, the medication safety is improved, and good clinical application prospects are achieved.

The invention relates to a specific liver microtissue, the largest dimension of which is between 500 and 700 μm, which expresses monooxygenase CYP3A4 with an activity of at least 75,000 RLU per million cells and produces at least 18 μg of urea per million cells in 24 hours. The invention also relates to a method for preparing a liver microtissue of this kind and to the uses thereof in the treatment or prevention of liver failure.

A system for managing liver disease, the system comprising an electronic medical record system comprising a plurality of patient records. The system comprising a patient management platform configured to access the electronic medical record (EMR) system to retrieve medical records of one or more patients, analyze the medical records to selectively identify data related to a liver condition, interface with one or more data analysis platforms configured to receive and analyze the data related to a liver condition. Based on analysis by the patient management interface and / or the data analysis platforms, a display is generated comprising: specific liver-related patient attributes and conditions, and at least one of: a liver health prognosis or a recommended treatment for addressing the liver condition corresponding to the one or more patients. The liver condition can comprise one or more of: cancer, cirrhosis, liver failure, fatty liver disease, steatosis, ischemia, and / or hepatitis.

This invention discloses a biomimetic decellularized matrix hydrogel and its applications. It relates to the field of biomaterials technology. It comprises the following components: decellularized liver matrix, gelatin, and sodium alginate, and its applications are provided. The therapeutic artificial liver provided by this invention can be mass-produced in vitro using 3D bioprinting technology, exhibiting mature liver functional phenotypes such as ICG uptake / release and drug metabolism in vitro. It was transplanted into a type I tyrosinemia model of liver failure (Fah). ‑ / ‑ It can alleviate liver damage in mice and has the potential for artificial liver transplantation.

Overt hepatic encephalopathy is a serious complication of cirrhosis and affects lipid and lipoprotein metabolism. The present invention relates to a biomarker for the prognosis of hepatic encephalopathy. The biomarker includes one or more of high-density lipoprotein cholesterol, model for end-stage liver disease score, age, gender, upper gastrointestinal bleeding, spontaneous bacterial peritonitis, overt hepatic encephalopathy grade, ascites, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum albumin, total cholesterol, low-density lipoprotein cholesterol, serum creatinine, neutrophil-lymphocyte ratio, prothrombin time, and prothrombin activity level. Compared with patients with alcoholic hepatitis, liver disease, liver failure, etc. proposed in the prior art, due to the specificity of the target population, the biomarker proposed in this application can significantly improve the accuracy of the assessment of the prognosis of overt hepatic encephalopathy.

Methods are disclosed for treating end-stage liver failure in a subject that include administering to the subject a therapeutically effective amount of a recombinant mRNA encoding HNF4α isoform 2. The methods can include administering a lipid nanoparticle including the recombinant mRNA to the subject. Also disclosed are recombinant mRNA encoding an HNF4α isoform 1 or HNF4α isoform 2, and lipid nanoparticles include the recombinant mRNA. Methods are also for treating liver disease or end-stage liver failure in a subject that include administering to the subject a therapeutically effective amount of a recombinant mRNA encoding HNF4α isoform 1.

The present application relates to a kind of protein combination, kit and system for predicting secondary infection of hepatitis B related liver failure patient, including the use of protein combination in the preparation for predicting secondary infection of hepatitis B related liver failure patient, the combination includes lysozyme LYZ, calmodulin 1 CALM1, heparin cofactor II SERPIND1 and cutin DPT.It is directly reflected that the combination is biomarker "inflammation-coagulation imbalance" this core mechanism of liver disease secondary infection, with high specificity, and the combination is not interfered by liver disease background, more can truly reflect the potential reaction state of body to infection under liver disease background, to overcome the problem of "failure" and "false negative" of traditional index ";The combination can significantly change concentration when patient is admitted to hospital early, without clinical infection signs, to provide key time window for early preventive treatment.

The invention provides an application of SETDB1 as a drug target for preventing and / or treating acute liver injury and hepatic failure. The acute liver injury and hepatic failure are relieved by knocking out an SETDB1 gene or inhibiting SETDB1 enzyme activity. Experiments prove that the SETDB1 gene is specifically knocked out of the liver or a small-molecule inhibitor SETDB1-TTD-IN-1 is used, acute liver injury and hepatic failure induced by acetaminophen can be remarkably relieved, and the acute liver injury and hepatic failure are shown as reduction of hepatic cell necrosis and remarkable improvement of liver function indexes. The discovery provides new targets and candidate compounds for developing specific drugs for treating acute liver injury and hepatic failure, and has important clinical transformation value.